Epitope-based minigene vaccine targeting fibroblast activation protein α induces specific immune responses and anti-tumor effects in 4 T1 murine breast cancer model

Zhang, Fang-Fang; Qiao, Yaru; Xie, Yu; Liu, Chenlu; Wu, Hui; Wu, Jiaxin; Yu, Xianghui; Kong, Wei; Zhang, Haihong

doi:10.1016/j.intimp.2022.109237

Cited by 7 publications

(2 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…So far, the use of DNA vaccines has been limited to animal experiments, and no DNA vaccines have moved into the clinic. Researchers have developed an FAP.291-based epitope minigene vaccine that can activate CTL against CAFs and suppress tumor progression in murine BC models [ 217 ]. Moreover, several drugs targeting FAP have been submitted to clinical trial-enrolled patients with metastatic CRC, including Sibrotuzumab (a FAP targeting humanized monoclonal antibody) and Talabostat [ 218 , 219 ].…”

Section: Background Knowledge Of Cafsmentioning

confidence: 99%

Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials

Zhang,

Yue,

Chen

et al. 2023

Mol Cancer

View full text Add to dashboard Cite

Despite centuries since the discovery and study of cancer, cancer is still a lethal and intractable health issue worldwide. Cancer-associated fibroblasts (CAFs) have gained much attention as a pivotal component of the tumor microenvironment. The versatility and sophisticated mechanisms of CAFs in facilitating cancer progression have been elucidated extensively, including promoting cancer angiogenesis and metastasis, inducing drug resistance, reshaping the extracellular matrix, and developing an immunosuppressive microenvironment. Owing to their robust tumor-promoting function, CAFs are considered a promising target for oncotherapy. However, CAFs are a highly heterogeneous group of cells. Some subpopulations exert an inhibitory role in tumor growth, which implies that CAF-targeting approaches must be more precise and individualized. This review comprehensively summarize the origin, phenotypical, and functional heterogeneity of CAFs. More importantly, we underscore advances in strategies and clinical trials to target CAF in various cancers, and we also summarize progressions of CAF in cancer immunotherapy.

show abstract

Section: Background Knowledge Of Cafsmentioning

confidence: 99%

Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials

Zhang,

Yue,

Chen

et al. 2023

Mol Cancer

View full text Add to dashboard Cite

show abstract

“…Gene-engineered tumor cell derived exosome-like vaccine (eNVs-FAP) developed by Hu S et al inhibits tumor progression by reducing the number of MDSCs, reprogramming TME and promoting tumor ferrocytosis (142). Another study has shown that a vaccine against fibroblast growth factor (FGF)-2 also reduced the number of MDSCs in mice bearing 4T1 mammary tumors (143). However, an epitope gene vaccine against fibroblast activating protein (FAP) a enhanced the antitumor immune response in BC models, but no improvement in antitumor effects was observed, which may be related to the vaccine-induced elevation of MDSCs (144).…”

Section: Immunotherapymentioning

confidence: 99%

MDSCs in breast cancer: an important enabler of tumor progression and an emerging therapeutic target

et al. 2023

View full text Add to dashboard Cite

Women worldwide are more likely to develop breast cancer (BC) than any other type of cancer. The treatment of BC depends on the subtype and stage of the cancer, such as surgery, radiotherapy, chemotherapy, and immunotherapy. Although significant progress has been made in recent years, advanced or metastatic BC presents a poor prognosis, due to drug resistance and recurrences. During embryonic development, myeloid-derived suppressor cells (MDSCs) develop that suppress the immune system. By inhibiting anti-immune effects and promoting non-immune mechanisms such as tumor cell stemness, epithelial-mesenchymal transformation (EMT) and angiogenesis, MDSCs effectively promote tumor growth and metastasis. In various BC models, peripheral tissues, and tumor microenvironments (TME), MDSCs have been found to amplification. Clinical progression or poor prognosis are strongly associated with increased MDSCs. In this review, we describe the activation, recruitment, and differentiation of MDSCs production in BC, the involvement of MDSCs in BC progression, and the clinical characteristics of MDSCs as a potential BC therapy target.

show abstract

Targeting fibroblast activation protein (FAP): advances in CAR-T cell, antibody, and vaccine in cancer immunotherapy

Shahvali

Rahiman

Jaafari

et al. 2023

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

Epitope-based minigene vaccine targeting fibroblast activation protein α induces specific immune responses and anti-tumor effects in 4 T1 murine breast cancer model

Cited by 7 publications

References 49 publications

Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials

Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials

MDSCs in breast cancer: an important enabler of tumor progression and an emerging therapeutic target

Targeting fibroblast activation protein (FAP): advances in CAR-T cell, antibody, and vaccine in cancer immunotherapy

Contact Info

Product

Resources

About